This Notice of Funding Opportunity (NOFO) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NIAID. This program provides support for hypothesis-driven, milestone-driven clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High-risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and may be proposed under this program.
Companion FOAs:
PAR-23-206 , R34 Planning Grant
PAR-24-100 , U01 Research Project (Cooperative Agreements)
Deadlines:
- Letter of Intent Due Date(s): 30 days before the application due date
- Application Due Date(s): May 13, 2024; Sep 13, 2024; Jan 13, 2025; May 13, 2025; Sep 15, 2025; Jan 13, 2026; May 13, 2026; Sep 14, 2026; Jan 13, 2027
- AIDS Application Due Date(s): May 13, 2024; Sep 13, 2024; Jan 13, 2025; May 13, 2025; Sep 15, 2025; Jan 13, 2026; May 13, 2026; Sep 14, 2026; Jan 13, 2027
PAR-24-099 Expiration Date: January 14, 2027
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.
NIAID will consider Phase I budget requests up to $300,000 total costs per year for up to 2 years (Fast-Track only); and Phase II or IIB budget requests up to $1,000,000 (total costs) per year for up to 3 years.